Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Down 5% – Should You Sell?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares traded down 5% on Thursday . The stock traded as low as $1.89 and last traded at $2.09. 370,047 shares changed hands during trading, an increase of 217% from the average session volume of 116,627 shares. The stock had previously closed at $2.20.

Phio Pharmaceuticals Stock Down 7.7 %

The firm has a market cap of $2.04 million, a P/E ratio of -0.18 and a beta of 1.49. The business’s 50 day moving average is $2.68 and its two-hundred day moving average is $3.48.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.